PFDN5

Across TCGA pan-cancer cohorts, PFDN5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PFDN5 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PFDN5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PFDN5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and COAD are the cancer types where PFDN5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.500	0.851	.001	21	view →
LSCC	DFS	Tertile	All	0.869	0.206	.001	10	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
GBM	OS	Quartile	All	0.964	0.725	.009	6	view →
HNSC	DFS	Tertile	III,IV	0.889	0.699	.022	2	view →
LUAD	DFS	Median	All	0.506	0.726	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PFDN5–CCRCC (DFS)

Open the CCRCC breakdown →